Meridian Financial’s Cytokinetics CYTK Stock Holding History

Meridian Financial’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,583	Closed	-$228K	–	145
2025 Q4	$228K	Sell	3,583 -535	-13%	-$33.3K	0.12%	132
2025 Q3	$226K	Buy	+4,118	New	+$170K	0.13%	128
2025 Q1	–	Sell	-4,318	Closed	-$203K	–	123
2024 Q4	$203K	Hold	4,318	–	–	0.14%	117
2024 Q3	$228K	Hold	4,318	–	–	0.15%	118
2024 Q2	$234K	Sell	4,318 -800	-16%	-$48.3K	0.17%	109
2024 Q1	$359K	Sell	5,118 -882	-15%	-$68.2K	0.27%	71
2023 Q4	$501K	Buy	+6,000	New	+$217K	0.39%	50
2023 Q3	–	Sell	-7,591	Closed	-$248K	–	96
2023 Q2	$248K	Hold	7,591	–	–	0.22%	82
2023 Q1	$267K	Buy	+7,591	New	+$310K	0.26%	76

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Meridian Financial's CYTK Position: Q1 2026 in Review

Meridian Financial sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 3,583 shares — an estimated $228K sold.

Meridian Financial first reported a position in CYTK in Q1 2023 and held it in 9 quarters. The position peaked at $501K in Q4 2023. 440 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Meridian Financial reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
Meridian Financial sold 3,583 Cytokinetics shares in Q1 2026, an estimated $228K.
Meridian Financial first reported a position in Cytokinetics in Q1 2023 and held it in 9 quarters.
Meridian Financial's Cytokinetics position peaked at $501K in Q4 2023.
440 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Meridian Financial's 13F filing for Q1 2026, filed 21 Apr 2026.